Development and validation of a radiomics-based model to predict local progression-free survival after chemo-radiotherapy in patients with esophageal squamous cell cancer

He-San Luo1*, Ying-Ying Chen1, Wei-Zhen Huang2, Sheng-Xi Wu1, Shao-Fu Huang1, Hong-Yao Xu1, Ren-Liang Xue1, Ze-Sen Du3, Xu-Yuan Li4, Lian-Xin Lin1 and He-Cheng Huang1

Abstract

Purpose: To develop a nomogram model for predicting local progress-free survival (LPFS) in esophageal squamous cell carcinoma (ESCC) patients treated with concurrent chemo-radiotherapy (CCRT).

Methods: We collected the clinical data of ESCC patients treated with CCRT in our hospital. Eligible patients were randomly divided into training cohort and validation cohort. The least absolute shrinkage and selection operator (LASSO) with COX regression was performed to select optimal radiomic features to calculate Rad-score for predicting LPFS in the training cohort. The univariate and multivariate analyses were performed to identify the predictive clinical factors for developing a nomogram model. The C-index was used to assess the performance of the predictive model and calibration curve was used to evaluate the accuracy.

Results: A total of 221 ESCC patients were included in our study, with 155 patients in training cohort and 66 patients in validation cohort. Seventeen radiomic features were selected by LASSO COX regression analysis to calculate Rad-score for predicting LPFS. The patients with a Rad-score $\geq 0.1411$ had high risk of local recurrence, and those with a Rad-score $< 0.1411$ had low risk of local recurrence. Multivariate analysis showed that N stage, CR status and Rad-score were independent predictive factors for LPFS. A nomogram model was built based on the result of multivariate analysis. The C-index of the nomogram was 0.745 (95% CI 0.770–0.790) in training cohort and 0.723 (95% CI 0.654–0.791) in validation cohort. The 3-year LPFS rate predicted by the nomogram model was highly consistent with the actual 3-year LPFS rate both in the training cohort and the validation cohort.

Conclusion: We developed and validated a prediction model based on radiomic features and clinical factors, which can be used to predict LPFS of patients after CCRT. This model is conducive to identifying the patients with ESCC benefited more from CCRT.

Keywords: Chemo-radiotherapy, Esophageal squamous cell cancer, Radiomics, LPFS, Nomogram

Introduction

Esophageal cancer (EC) is the sixth common malignant tumors in China with an estimated 477.9 thousand new cases, accounting for half of the new esophageal cancer
worldwide [1, 2]. In China, approximately 90% of the patients with esophageal cancer are histologically diagnosed as esophageal squamous cell carcinomas (ESCC) which is different from esophageal adenocarcinoma (EAC) in risk factors and prognosis [3]. Most patients with locally advanced ESCC lost the opportunity for surgery, and concurrent chemo-radiotherapy (CCRT) has been recommended as a standard treatment [4]. However, more than half of patients treated with standard dose CCRT eventually developed local recurrence or distant metastases and succumbed to this disease [5, 6]. A individual CCRT strategy with escalated radiation dose based on PET-CT would benefit the patients with high tumor burden and risk of recurrence [7, 8]. To facilitate a individual CCRT strategy in an early stage, solid predictive model for local recurrence and prognosis could play an important role.

For patients received CCRT, local and regional recurrence is the most common failure pattern and pre-treatment clinical TNM staging is still the most commonly used system for prognosis prediction [9]. However, the currently used clinical TNM staging follows the same criteria as pathological staging, which is based on imaging assessment of tumor size and surrounding invasion, ignoring the information such as length and volume of esophageal cancer lesions. Recently, a series of clinical-pathologic biomarkers have been investigated and verified to be available for prediction of therapeutic response and prognosis [10–12]. Radiomics is a new technique for image quantitative analysis about computed tomography (CT) images, magnetic resonance (MR) images, positron emission tomography (PET) images, etc. [13]. Several studies demonstrated that radiomic features could potentially identify prognostic phenotype in patients with EC. Yip et al. [14] suggested that a model combined CT-based texture feature and esophageal maximal wall thickness assessment could predict the overall survival in EC patients treated with CCRT. Moreover, the model performed better than treatment response alone. Larue et al. [15] extracted out five radiomic features from CT image before chemoradiotherapy to describe the heterogeneity of tumors and found that these five features could predict the 3-year survival rate of patients with EC after neo-chemoradiotherapy. However, most radiomic studies included a small number of patients with EAC and ESCC.

In this study, we explored the prognostic value of 3D radiomic features from pretreatment CT images of esophageal cancer patients and developed a model combined radiomic features and clinical information to predict LPFS in patients with ESCC after CCRT. To evaluate the performance of the model, a validation cohort of patients were employed for validation.

Patients and methods

Patients’ cohort

We collected the clinical data of patients diagnosed as ESCC and received CCRT in our hospital during the period from January 2013 to December 2015. Patients were excluded if they met the exclusion criteria as follows: (1) patients received esophagectomy and preoperative or postoperative adjuvant radiotherapy; (2) patients had distant metastatic disease; (3) patients received low-dose (<50 Gy) palliative radiotherapy; (4) clinicopathological information of the patients was incomplete; (5) patients were diagnosed as esophageal fistula before treatment; (6) poor visualization quality due to image artifacts or the tumor was too small to be recognized on CT images; (7) patients had other primary tumor; (8) patients died within three months after chemoradiotherapy.

After multiple iterations, a total of 221 patients were randomly divided into two groups, with 155 patients in the training cohort and 66 patients in the validation cohort. To improve the generalization property of the result, multi-factors stratification was used to keep the characteristics of sub cohort consistent with the whole cohort. The process of patients’ enrollment and randomization were shown in Fig. 1. This study was approved by the Institutional Committee of our hospital on Human Rights. Disease of the patients was staged according to the 8th edition of AJCC TNM classification for esophageal cancer [16].

Chemoradiotherapy protocol

Radiotherapy was delivered daily to patients with three-dimensional conformal radiation therapy (3DRT) or intensity-modulated radiation therapy (IMRT) technique using a Varian IX or Varian 23EX linear accelerator in this study. The gross tumor volume (GTV) includes the esophageal cancer (GTVp) and the positive regional lymph nodes (GTVnd). The GTV was delineated on CT imaging according to barium esophagogram, endoscopic examination or PET imaging. The CTV was defined as the GTVp with 0.5–1 cm radial expansion and 2.5–3 cm axial direction expansion or the GTVnd with 0.5–0.8 cm uniform expansion. The planning target volume (PTV) was defined as CTV with a 1 cm uniform expansion. A total prescribed dose of 50–72 Gy (median, 64 Gy) in conventional fractionation was delivered to the patients.

Two cycles of platinum-based chemotherapy were administered concurrently with radiotherapy. Sixty-one patients received TP (paclitaxel+cisplatin) chemotherapy every three weeks, which consists of cisplatin (60 mg/m² on Day 1) plus paclitaxel (135–180 mg/m² on Days 1). One hundred and sixty patients received the PF (cisplatin+fluorouracil) regimen every four weeks,
Fig. 1 Flow chart of patients' screening and allocation

Patients with EC underwent radiotherapy January 2013 and December 2015 N=437

- Patients received esophagectomy and adjuvant radiotherapy n=131

All patients received chemoradiotherapy alone N=306

- Patients diagnosed as adenocarcinoma or other pathological types n=17

All patients were pathologically proven ESCC N=289

- Patients with
  1) distant metastatic disease (n=13)
  2) multiple esophageal cancers (n=11)
  3) esophageal stent implantation (n=7)

All patients were diagnosed as non-metastatic disease N=257

- Patients
  1) underwent palliative radiotherapy (doses <50 Gy) (n=7)
  2) failed to complete therapy (n=3)

All patients received radiotherapy doses >50 Gy N=247

- 1) Patients with KPS of 10-50 (n=13)
  2) patients died within 3 months after radiotherapy (n=4)
  3) patients died in an accident within 6 months (n=1)

All patients were in good performance status (KPS>60) N=229

- Patients with
  1) incomplete clinical data (n=5)
  2) unclear medical image (n=3)

Patients were finally included this study N=221

7:3 randomize

Training set N=155

Validation set N=66
which consists of cisplatin (60 mg/m² on Day 1) and fluorouracil (750 mg/m²/24 h on Days 1–4).

Response evaluation
The response to chemo-radiotherapy was evaluated one month after CCRT according to the criteria of short-term response evaluation standard on esophageal cancer using CT images and barium esophagogram. According to the response evaluation criteria, clinical response was classified as complete response (CR), partial response (PR), no response (NR), or progressive disease (PD). Patients who were classified as CR by barium esophagogram and had the maximal esophageal wall thickness of ≤1.2 cm and the volumes of residual lymph nodes of ≤1.0 cm³ on CT were finally defined as CR [17].

Radiomic feature extraction
All patients were scanned using GE Lightspeed 64-slice spiral CT (GE Medical systems, Milwaukee, Wis) before radiotherapy. CT image acquisition was performed according to the following acquisition protocol: The CT tube voltage was 120 kV and the tube current was 120 mAs. Rack rotation time: 0.6 s; Detector collimation parameters: 64 × 0.625 mm; field of view (FOV): 400-500 mm; Matrix: 512 × 512; Layer thickness is 5 mm, layer spacing is 5 mm. Contrast medium was injected with a high-pressure syringe at a flow rate of 3.0 ml/s (1–1.5 ml/kg, ioproxamine injection 300), followed by 30 to 40 ml of normal saline for flushing, and late arterial CT images were collected with a delay of 30 s. To reduce the variability between images from different patients, all images were resampled to voxel of 1×1×1mm³.

3D Slicer (version, 4.10.2, Stable Release) with radiomics extension was used for image segmentation to obtain volume of interest (VOIs). The primary tumor volume (GTV) delineated by radiation oncologists for radiotherapy treatment planning design was defined as VOI for radiomic features extraction. Any pixel with an attenuation lower than −50 HU was excluded to avoid adjacent air, fat, blood vessels and surrounding organs. Image segmentation was performed independently by a radiation oncologist and another radiologist. To assess the reproducibility of the radiomic features extraction, tumor segmentation was performed again two months later by the same radiologist in 30 randomly chosen patients.

Pyradiomics V3.6.2 was used to extract radiomic features from delineated VOIs. Several categories of features were extracted from VOIs, including first order statistics features (IH, intensity histogram), shape-based histogram features, and texture features (gray-level co-occurrence matrix, GLCM; gray-level size-zone matrix, GLSZM; gray-level run-length matrix, GLRLM; neighboring gray-tone difference matrix, NGTDM; and gray-level dependence matrix, GLDM). The wavelet filter was used in image pre-processing for texture features extraction. In all, for each VOI, 107 original features (Additional file 1: Table S1) and 744 wavelet features (Additional file 1: Table S1) were collected. Among the 107 original features, there were 18 first order statistics features, 14 shape-based histogram features, 24 GLCM features, 14 GLDM features, 16 GLRLM features, 16 GLSZM features and 5 NGTDM features. Mathematical definitions of these radiomic features have previously been described [18] and available at https://pyradiomics.readthedocs.io/en/latest/features.html.

Statistical analysis
At the first, statistical analyses were performed with Chi-squared test or Fisher’s to assess the difference of the clinical characteristics between training cohort and validation cohort. A p-value of < 0.05 was considered statistically significant.

In the pre-processing of radiomic features, all the values of radiomic features were normalized using Z-score normalization, which made features values lying within similar ranges and reduced the influence of large discrete values. The intra-class correlation coefficient (ICC) analysis was performed to evaluate the reproducibility of each radiomic feature. Only the features with ICCs values ≥0.900 were selected for further analysis. Then, the least absolute shrinkage and selection operator (LASSO) with Cox regression was performed using R software version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria) to identify the features associated with LPFS in the training cohort. The optimal parameter lambda (λ) was chosen from the LASSO model using ten-fold cross-validation with the minimum partial likelihood deviance. Radiomic feature score (Rad score) for each patient was built based on the LASSO COX regression model in the training cohort. The LASSO COX regression formula:

\[
\text{Rad score} = \beta_1X_1 + \beta_2X_2 + \beta_3X_3 + \cdots + \beta_nX_n
\]

In the above formula, X1, X2 ... Xn are the different radiomic features identified by the LASSO COX regression model, and \(\beta_1, \beta_2, ..., \beta_n\) are the regression coefficients of the corresponding features in the regression model.

Univariate analysis was performed to identify the potential prognostic factors associated with LPFS. Multivariable COX regression analysis was performed to identify the independently predictors for LPFS. A nomogram model combined Rad-score and clinical factors for predicting LPFS was developed and validated based on the results of multivariable COX regression analysis using rms package and foreign package in R software. The
predictive accuracy of the nomogram model was assessed using Calibration curve validation in both training cohort and validation cohort. All the analyses were performed with R software version 3.6.2.

Results

Patients’ characteristics

A total of 221 ESCC patients who received chemoradiotherapy in our hospital were eligible for further analysis in this study. Patients’ characteristics were summarized in Table 1. The median follow-up time was 18.6 months. By the end of the last follow-up, 153 patients developed local regional disease progression or died. The median LPFS in the whole group was 13.7 months, and the rates of 1-year, 2-year and 3-year LPFS were 56.1%, 37.4% and 32.1%, respectively (Fig. 2).

In order to develop and validate a radiomics-based model for predicting LPFS of the patients, they were randomly divided into training cohort and validation cohort. There were 155 patients in the training cohort and 66 patients in the validation cohort. No significant differences (All \( p > 0.05 \)) were found between the distribution of baseline characteristics in two cohorts, such as age, gender, tumor location, T stage, N stage, clinical staging, lactate dehydrogenase (LDH), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and CR ratio (33.5% in the training cohort vs 39.4% in the validation cohort). Therefore, the two cohorts of patients were comparable.

Table 1  Comparison of patients’ characteristics between training cohort and validation cohort

| Variables            | Training cohort (n = 155) | Validation cohort (n = 66) | \( \chi^2/t \) | \( p \) |
|----------------------|--------------------------|---------------------------|---------------|-------|
| Age (years), Mean±SD | 65.7147 ± 9.74           | 64.73 ± 10.16             | 0.678         | 0.499 |
| Gender               |                          |                           |               |       |
| Male                 | 116 (74.8)               | 45 (68.2)                 | 0.342         | 0.559 |
| Female               | 39 (25.2)                | 21 (31.8)                 |               |       |
| Tumor location       |                          |                           | 5.814         | 0.121 |
| Cervical             | 6 (3.9)                  | 8 (12.1)                  |               |       |
| Upper thoracic       | 34 (21.9)                | 16 (24.2)                 |               |       |
| Middle thoracic      | 91 (58.7)                | 33 (50.0)                 |               |       |
| Lower thoracic       | 24 (15.5)                | 9 (13.6)                  |               |       |
| T stage              |                          |                           | 3.193         | 0.363 |
| T1                   | 2 (1.3)                  | 0 (0)                     |               |       |
| T2                   | 11 (7.1)                 | 9 (13.6)                  |               |       |
| T3                   | 66 (42.6)                | 27 (40.9)                 |               |       |
| T4                   | 76 (49.0)                | 30 (45.5)                 |               |       |
| N stage              |                          |                           | 1.856         | 0.603 |
| N0                   | 20 (12.9)                | 13 (19.7)                 |               |       |
| N1                   | 70 (45.2)                | 28 (42.4)                 |               |       |
| N2                   | 55 (35.5)                | 22 (33.3)                 |               |       |
| N3                   | 10 (6.5)                 | 3 (4.5)                   |               |       |
| Clinical stage       |                          |                           | 3.152         | 0.369 |
| I                    | 2 (1.3)                  | 0 (0)                     |               |       |
| II                   | 15 (9.7)                 | 11 (16.7)                 |               |       |
| III                  | 88 (56.8)                | 37 (56.1)                 |               |       |
| Iva                  | 50 (32.3)                | 18 (27.3)                 |               |       |
| Radiation dose, Median (range) | 64 (60–66) | 64 (60–66) | −0.920 | 0.358 |
| LDH group            |                          |                           | 1.282         | 0.258 |
| High                 | 88 (56.8)                | 32 (48.5)                 |               |       |
| Normal               | 67 (43.2)                | 34 (51.5)                 |               |       |
| NLR, Median (range)  | 2.73 (1.96–3.71)         | 2.76 (2.00–3.63)          | −0.448        | 0.654 |
| PLR, Median (range)  | 137.78 (100.56–181.43)   | 138.87 (101.31–182.26)    | −0.344        | 0.731 |
| CR ratio             | 52 (33.5)                | 26 (39.4)                 |               |       |
| Rad-score, Mean±SD   | −0.0289 ±0.35            | −0.058 ±0.538             | 0.474         | 0.636 |
Rad-score building based on radiomic features

LASSO-COX regression was used to screen out the optimal radiomic features associated with LPFS of the patients in the training cohort (Fig. 3A, B). As a result, seventeen radiomic features were screened out (The features and their coefficients were listed in the Table 2). The Rad-score was calculated as follows:

$$\text{Rad-score} = -0.104667846 \times \text{original_firstorder_Skewness} + 0.001161134 \times \text{origin_glszm_SizeZoneNonUniformityNormalized} + 0.034339901 \times \text{origin_glszm_SizeZoneNonUniformity} - 0.017089976 \times \text{origin_glszm_LowGrayLevelZoneEmphasis} + 0.062595767 \times \text{wavelet-HLL_gldcm_Idn} + 0.026703955 \times \text{wavelet-HLL_firstorder_Maximum} + 0.042957143 \times \text{wavelet-HLL_glszm_SizeZoneNonUniformityNormalized} + 0.017543973 \times \text{wavelet-LHL_firstorder_TotalEnergy} + 0.003781538 \times \text{wavelet-LHL_firstorder_Myopia} - 0.007364328 \times \text{wavelet-LHL_gldcm_SmallDependenceLowGrayLevelEmphasis} + 0.157807433 \times \text{wavelet-LLH_gldcm_DifferenceVariance} + 0.042028490 \times \text{wavelet-LLH_glm_MyopiaHighGrayLevelEmphasis} - 0.101981005 \times \text{wavelet-LLH_ngtdm_Coarseness} - 0.073958943 \times \text{wavelet-LLH_gldcm_SmallDependenceLowGrayLevelEmphasis} + 0.051287394 \times \text{wavelet-LLH_firstorder_Myopia} - 0.055239045 \times \text{wavelet-HHH_gldcm_MyopiaHighGrayLevelEmphasis} - 0.028958889 \times \text{wavelet-LLH_gldcm_Imc2}.$$

There was an optimal cutoff value of Rad score to divide the patients into two groups with different risk of local recurrence. As shown in Fig. 3C, the patients with a Rad-score ≥ 0.1411 had high risk of local recurrence, and those with a Rad-score < 0.1411 had low risk of local recurrence. In the training cohort, the patients in the group with high risk of local recurrence had significantly shorter time of LPFS than those with risk of local recurrence (Fig. 4A, HR 2.882, 95% CI 1.926–4.313, p < 0.001).

The same result was found in the validation cohort (Fig. 4B, HR 1.997, 95% CI 1.070–3.728, p = 0.026).

Development and validation of a predictive nomogram based on Rad-score

In order to develop a model to predict LRFS based on multiple factors, we performed univariate and multivariate analyses to identify predictive factors for LPFS. Univariate analysis showed that the T stage, N stage, clinical stage and CR status were significantly associated with LPFS both in training cohort and validation cohort (Table 3). Multivariate analysis showed that N stage, CR status and Rad-score were independent predictive factors for LPFS in ESCC patients after chemoradiotherapy (Table 4). A nomogram model for predicting LPFS was built based on the result of multivariate analysis (Fig. 5A). As shown in Fig. 5 1-year, 2-year and 3-year LPFS probability of every patient could be predicted based on the independent clinical characteristics and Rad-score. The C-index of the nomogram was 0.745 (95% CI 0.770–0.790) in training cohort and 0.723(95% CI 0.654–0.791) in validation cohort.

Finally, we performed calibration curve to evaluate the accuracy of the nomogram model. As shown in Fig. 6, the 3-year LPFS rate predicted by the nomogram model based on Rad-score was highly consistent with the actual 3-year LPFS rate both in the training cohort and the validation cohort.

Discussion

Concurrent chemoradiotherapy (CCRT) is a radical treatment for patients with inoperable esophageal cancer or refused surgery [4]. Many studies have shown that dose-escalation radiotherapy properly can improve the local control and survival of patients with ESCC [19–22]. Nevertheless, 30–50% of patients have local recurrence within 3 years [23–25]. In our present study, we constructed a prediction model combined the clinical characteristics and CT radiomic features which can predict the LPFS of patients after CCRT. With the help of this model, we can preliminarily judge the probability of LPFS of patients and identify the patients benefit more from CCRT.

Radiomics studies in esophageal cancer started relatively late, and there are still few data about applying radiomics analysis to evaluate the prognosis of esophageal cancer. Ganeshan et al. [26] first analyzed the radiomic features of CT before treatment in esophageal cancer patients and found that the radiomic features representing uniformity parameters were significantly different between stage I/II and stage III/IV disease, which were independent predictors of patients’ prognosis. Subsequently, Yip et al. [14] found that the tumor heterogeneity
could be represented by the change of CT radiomic features before and after neoadjuvant treatment, which was related to the prognosis and survival of patients. Larue et al. [15] also found that five radiomic features extracted from CT before chemoradiotherapy could be used to describe the tumor heterogeneity and predict the 3-year survival rate of patients after neoadjuvant chemoradiotherapy and surgery with AUCs (AUC, area under the receiver) of 0.69 in the training group and 0.61 in the validation group. All these studies suggested that radiomic features played an important role in evaluating the prognosis of esophageal cancer and could be used to predict the long-term survival of esophageal cancer patients after chemoradiotherapy, which was also supported in our study.

Clinical TNM staging before treatment is still the most commonly used prediction system of prognosis for ESCC patients treated with chemoradiotherapy. Combination of TNM staging and other prognostic factors can predict the prognosis of patients more individually and accurately [27, 28]. Some studies have shown that the prognosis of patients who achieved CR after chemoradiotherapy was better than that of patients not CR [29, 30]. Therefore, CR after CCRT had become another important predictor for the prognosis of patients besides clinical stages. In the present study, univariate analysis showed
that pre-treatment clinical T stage, N stage, clinical stage and CR after radiotherapy were the prognostic factors related to LPFS after CCRT. Moreover, Rad-score based on 17 radiomic features extracted from CT images before chemoradiotherapy was significantly related to LPFS of patients after chemoradiotherapy. Further multivariate analysis showed that Rad-score, N stage and CR after radiotherapy were independent predictors of patients’ LPFS, while T stage and clinical stage had no statistical significance in this multivariate analysis model, probably because Rad-score derived from the primary tumor focus and had interactive effects with T stage and clinical stage. We developed and validated a nomogram model based on the results of multivariate analysis. C-index and calibration curve were used to evaluate the performance and prediction accuracy of the nomogram model. The C-index of the model was 0.745 (95% CI 0.700–0.790) in the training cohort and 0.723 (95% CI 0.654–0.791) in the validation cohort, indicating high prediction accuracy.

Table 2 Radiomics feature associated with LPFS selected by LASSO COX analysis

| Radiomics features                                      | Coefficients |
|---------------------------------------------------------|--------------|
| original_firstorder_Skewness                            | −0.104667846 |
| origin_glszm_SizeZoneNonUniformityNormalized           | 0.001161134  |
| origin_glszm_SizeZoneNonUniformity                      | 0.034339901  |
| origin_glszm_LowGrayLevelZoneEmphasis                  | −0.017089976 |
| wavelet-HLL_glcmm_Mean                                    | 0.062595767 |
| wavelet-HLL_firstorder_Maximum                           | 0.026703955  |
| wavelet-HLL_glszm_SizeZoneNonUniformityNormalized       | 0.042957143  |
| wavelet-LHL_firstorder_TotalEnergy                       | 0.017543973  |
| wavelet-LHL_firstorder_Maximum                           | 0.003781538  |
| wavelet-LH_HL_gldm_SmallDependenceLowGrayLevelEmphasis | −0.007364328 |
| wavelet-LH_LH_firstorder_TotalEnergy                     | 0.157807433  |
| wavelet-LH_LH_firstorder_Maximum                         | 0.042028490  |
| wavelet-HH_HL_gldm_SmallDependenceLowGrayLevelEmphasis | −0.073958943 |
| wavelet-HL_HL_firstorder_Maximum                         | 0.051287394  |
| wavelet-HL_LH_gldm_Mean                                   | −0.101981005 |
| wavelet-LH_HL_gldm_Mean                                   | −0.028958889 |

Table 4 Multivariate analysis of prognostic factors associated with LPFS for patients with ESCC treated with chemoradiotherapy

| Variables | HR        | 95% CI            | p     |
|-----------|-----------|-------------------|-------|
| T stage   | 0.858     | 0.526–1.400       | 0.540 |
| N stage   | 1.892     | 1.122–3.190       | 0.017 |
| Clinical stage | 0.627 | 0.313–1.258       | 0.189 |
| Rad-score | 4.423     | 1.993–9.814       | 0.000 |
| CR status | 0.154     | 0.080–0.297       | 0.000 |

Fig. 4 Kaplan-Meier survival curve of patients with high and low recurrence risk based on Rad-score. A LPFS survival curve of patients in the training cohort: green line represents patients with low risk of local recurrence and red represents patients with high risk of local recurrence. The difference is significant between two groups, p < 0.001. B LPFS survival curve of patients in the validation cohort: green line represents patients with low risk of local recurrence and red line represents patients with high risk of local recurrence. The difference is significant between two groups, p = 0.026
performance. The calibration curve also showed a high prediction accuracy. Therefore, we believe that this prediction model based on Rad-score can provide a more accurate tool to predict LPFS, which was a convenient and economical means.

Although a prognosis prediction model was established and validated, there are some challenges for interpretation of the results. Due to the fact that the machine and scanning parameters of CT in other centers are usually different and not standardized, the utility of the results or the radiomic features in other study was full of uncertainty. Moreover, radiomic-biology correlations have not yet to be identified in published literature and clinical experience, so there is no concrete interpretation about the features or the feature sets. On the other hand, different methodologies for feature selection and the focus on

Table 3  Univariate analysis of prognostic factors associated with LPFS in patients with ESCC treated with chemoradiotherapy

| Variables       | Training cohort    |       |           |      | Validation cohort |       |           |      |
|-----------------|--------------------|-------|-----------|------|-------------------|-------|-----------|------|
|                 | HR                 | 95% CI| p         |      | HR                | 95% CI| p         |      |
| Age             | 0.987              | 0.967–1.007 | 0.202 |      | 0.984             | 0.957–1.011 | 0.252 |      |
| Gender          | 1.639              | 1.014–2.650 | 0.044 |      | 1.198             | 0.652–2.202 | 0.560 |      |
| Tumor location  | 1.120              | 0.851–1.473 | 0.419 |      | 1.289             | 0.917–1.812 | 0.143 |      |
| T stage         | 2.015              | 1.453–2.793 | <0.001 |      | 1.943             | 1.227–3.077 | 0.005 |      |
| N stage         | 1.867              | 1.446–2.410 | <0.001 |      | 1.765             | 1.215–2.563 | 0.003 |      |
| Clinical stage  | 2.194              | 1.581–3.044 | <0.001 |      | 2.309             | 1.440–3.704 | 0.001 |      |
| Radiation dose  | 0.965              | 0.923–1.009 | 0.118 |      | 0.996             | 0.921–1.078 | 0.927 |      |
| LDH             | 1.641              | 1.116–2.414 | 0.012 |      | 1.369             | 0.778–2.408 | 0.276 |      |
| NLR             | 1.069              | 0.965–1.184 | 0.199 |      | 1.015             | 0.901–1.142 | 0.810 |      |
| PLR             | 1.001              | 0.999–1.003 | 0.177 |      | 1.001             | 0.999–1.004 | 0.377 |      |
| CR status       | 0.128              | 0.072–0.228 | <0.001 |      | 0.295             | 0.157–0.556 | <0.001 |      |

Fig. 5  Nomogram model for predicting LPFS based on Rad-score. Rad.score refers to Rad-score. 0, 1, 2, and 3 refers to N0, N1, N2 and N3 in N stage line respectively. CR represents complete response, the value of 0 and 1 refer to non-CR and CR status respectively.

Fig. 6  Calibration curve validation for Nomogram model in training cohort (A) and validation cohort (B). The horizontal axis represents the predicted 3-year LPFS and the vertical axis represents the actual 3-year LPFS. The blue diagonal dot line represents the ideal nomogram, and the red line represents the observed nomogram. The closer the calibration curve is to the diagonal line, the higher the consistency between the predicted results and the actual situation.
different feature sets could have led to different results. These issues have also been addressed in other studies [31].

Our study provides a good enlightenment to the coming studies to prospectively establish patient cohorts. However, there are some defects worth noting. First of all, this study is a retrospective study. Because of the long-time span of CT images used in image data acquisition, there were inevitably some problems that the image quality and scanning parameters were hard to be exactly the same, especially the development time and dosage of enhancer, so this study only collects the information of plain CT images. Secondly, as patients’ response to chemoradiotherapy could not be evaluated pathologically, clinical CR used in our study can’t represent pathological CR completely truly. Fortunately, a considerable number of patients achieved CR had been confirmed by gastroscopy pathology. Being limited by the nature of a single-center retrospective study, the results may be biased to some extent, and its reliability and universality still need different centers to further carry out large sample size research verification.

Conclusion
In a word, this study established and validated a prediction model based on radiomic features and clinical factors, which can be used to predict LPFS of patients after CCRT. As an intuitive and convenient prediction method, this model is conducive to identifying the patients with ESCC benefited more from CCRT.

Abbreviations
ESCC: Esophageal squamous cell cancer; CCRT: Concurrent chemo-radiation therapy; CR: Complete response; LPFS: Local progress-free survival; LASSO: Least absolute shrinkage and selection operator; AUC: Area under the receiver operating characteristic curve; 3DRT: Three-dimensional conformal radiation therapy; GTV: Gross tumor volume; GTVnd: Nodal gross tumor volume; CTV: Clinical target volume; CTVt: Tumor clinical target volume; CTVnd: Nodal clinical target volume; PTV: Planning target volume; VOI: Volume of interest; GLCM: Gray-level co-occurrence matrix; GLSZM: Gray-level size-zone matrix; GLRLM: Gray-level run-length matrix; NGTDM: Neighboring gray-tone difference matrix; GLDM: Gray-level dependence matrix.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13014-021-01925-z.

Acknowledgements
None.

Authors’ contributions
He-San Luo designed the study. He-San Luo, Wei-Zhen Huang and Ying-Ying Chen prepared figures and wrote the manuscript text. Hong-Yao Xu, Ren-Liang Xue, and Shao-Fu Huang collected the follow-up data. Sheng-Xi Wu, Ze-Sen Du and Xu-Yuan Li made statistical analysis. All authors reviewed the manuscript and approved the final manuscript.

Funding
None.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Conflict of interest
Authors declare that there is no conflict of interest.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Author details
1 Department of Radiation Oncology, Shantou Central Hospital, Shantou 515000, Guangdong, China. 2 Department of Medical Oncology, Huizhou Municipal Central Hospital of Guangdong Province, Huizhou, China. 3 Department of Surgical Oncology, Shantou Central Hospital, Shantou, Guangdong, China. 4 Department of Medical Oncology, Shantou Central Hospital, Shantou, Guangdong, China.

Received: 2 June 2021 Accepted: 24 September 2021
Published online: 12 October 2021

References
1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
2. Malhotra GK, Yañala U, Raviganti A, et al. Global trends in esophageal cancer. J Surg Oncol. 2017;115:566–79.
3. Zeng H, Zheng R, Zhang S, et al. Esophageal cancer statistics in China, 2011: estimates based on 177 cancer registries. Thorac Cancer. 2016;7:232–7.
4. Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:855–83.
5. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.
6. Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118:2632–40.
7. Li Y, Zscheick S, Lin Q, et al. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation. Radiat Oncol. 2019;14:35.
8. Nkhali L, Thureau S, Edet-Sanson A, et al. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: reducing target volumes to deliver higher radiotherapy doses. Acta Oncol. 2015;54:909–15.
9. Wang WP, He SL, Yang YS, Chen LQ. Strategies of nodal staging of the TNM system for esophageal cancer. Ann Transl Med. 2018;6:77.
10. Luo HS, Xu HY, Du ZS, et al. Impact of sex on the prognosis of patients with esophageal squamous cell cancer underwent definitive chemoradiotherapy: a propensity score-matched analysis. Radiat Oncol. 2019;14:74.
11. Yang Z, He B, Zhuang X, et al. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. J Radiat Res. 2019;60:538–45.
12. Hu P, Liu Q, Deng G, et al. Radiosensitivity nomogram based on circulating neutrophils in thoracic cancer. Future Oncol. 2019;15:727–37.
13. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.
14. Yip C, Landaú D, Kozarzki R, et al. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemoradiotherapy and radiation therapy. Radiology. 2014;270:141–8.
15. Larue R, Klaassen R, Jochems A, et al. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncol. 2018;57:1475–81.
16. Rice TW, Gress DM, Patil DT, et al. Cancer of the esophagus and esophagogastric junction—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:304–17.
17. Chun H, Xue-jiao R, Lan W, et al. Evaluating short-term radiotherapeutic effect on esophageal cancer by barium meal combined with CT scans. Chin J Radiat Oncol. 2013;22:26–9.
18. van Griethuysen JIM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7.
19. Li C, Ni W, Wang X, et al. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal cancer. Radiat Oncol. 2019;14:48.
20. Lin FC, Chang WL, Chiang NJ, et al. Radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy. PLoS ONE. 2020;15:e0237114.
21. Zhang W, Luo Y, Wang X, et al. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy. Cancer Manag Res. 2018;10:2675–82.
22. Zhang W, Zhao J, Han W, et al. Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). Ann Transl Med. 2020;8:1140.
23. Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:383–91.
24. Zhou S, Zhang L, Luo L, et al. Failure pattern of elective nodal irradiation for esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy. Jpn J Clin Oncol. 2018;48:815–21.
25. Zhu SC, Li QF, Zhang XY, et al. Clinical outcomes of different irradiation ranges in definitive intensity-modulated radiotherapy for esophageal cancer. Zhonghua Zhong Liu Za Zhi. 2020;42:1040–7.
26. Ganeshan B, Skogen K, Pressney L, et al. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol. 2012;67:157–64.
27. Zhang X, Wang Y, Qu P, et al. Prognostic value of tumor length for cause-specific death in resectable esophageal cancer. Ann Thorac Surg. 2018;106:1038–46.
28. Zhiguo Z, Xin W, Lan W, et al. Effect of tumor length on clinical stage for non-operative esophageal squamous cell carcinoma patients—multi-center retrospective data analysis (3JECROG R-01D). Chin J Radiat Oncol. 2019;28:490–4.
29. Liu SL, Xi M, Yang H, et al. Is There a correlation between clinical complete response and pathological complete response after neoadjuvant chemoradiotherapy for esophageal squamous cell cancer? Ann Surg Oncol. 2016;23:273–81.
30. Li Z, Shan F, Wang Y, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis. PLoS ONE. 2018;13:e0189294.
31. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.